Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. - Wikidata - awgldk - TriplyDB

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

http://www.wikidata.org/entity/Q34326110

about

Alemtuzumab for multiple sclerosis Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use Alemtuzumab for Multiple Sclerosis.Alemtuzumab for the treatment of multiple sclerosis Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys The use of immune modulating drugs for the treatment of multiple sclerosis.Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.An improved method on isolation and serial passage of Chlamydia pneumoniae from human peripheral blood mononuclear cells.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Current evaluation of alemtuzumab in multiple sclerosis.Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.Drug safety evaluation of alemtuzumab for multiple sclerosis.Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.Establishment a CHO Cell Line Expressing Human CD52 Molecule.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.The immunological function of CD52 and its targeting in organ transplantation.Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation Dendritic cells as therapeutic targets in neuroinflammation.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.The outlook for alemtuzumab in multiple sclerosis.Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice.CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation.Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes following Lung Transplantation.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis.HIV vaccine candidate activation of hypoxia and the inflammasome in CD14 monocytes is associated with a decreased risk of SIV acquisition Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

P2860

Q24185899-56F44B53-244C-4EAB-A74A-292B4DED6A65 Q26800128-F81F2BF5-B4D2-477E-AD8F-0B36C1548BAC Q26849781-82272296-A1A8-4526-83F4-F3BCB8D32E7E Q28069730-47FEC6B4-DAF4-40B8-A073-AC3DB1FF4592 Q28080506-0A25FCC2-3333-4334-8F26-2069F0C37CEB Q33407411-3CBC23B6-48FA-4C48-872F-0DDAF7091CD4 Q33430760-40B7330A-4141-4725-A51B-CBC5E197B1E9 Q33434322-7B7AE3F4-03D5-4416-87C5-1986C3BCDD29 Q33933551-A554667E-9053-4B77-8265-4598E6EBFC8D Q35953466-B5FCEB74-38DA-4FE5-967B-99EBCE6763FB Q36113098-D6BDE056-DB0A-4310-A550-37D0AFE2A440 Q37337775-328E27DC-7AB8-4352-837A-A2EE8D0A07BF Q37362699-50959EFD-FE6C-4611-8137-8E2BFAB43AC6 Q37577290-33D3CA6C-A641-4857-B3C6-EE073AD07E83 Q37652611-EC2E67E1-74B3-4350-81F8-D34521632044 Q37845555-5EAC1BA8-3A9D-4454-AA3C-4C2E52FC2B5D Q38068494-5BE7E903-FECC-435F-8F4A-B6ADD7EAB55F Q38167350-9ACC86B8-1BEF-468E-919A-F3AF1B6567D6 Q38173374-F7C284D2-766C-417C-8678-AE99E3CCC0FE Q38220740-C0A3F15E-91AC-447B-A57C-D9DFAC9E365C Q38262622-FC44EEC8-F946-4F5F-8ACB-9E9D9E643980 Q38371740-F72CF0FC-841C-436D-ACA5-D09009A0498F Q38619696-2E5C12B1-843C-4BED-845E-002E97A211D8 Q38722163-C88C1E78-3CC2-4CDF-88E6-9CF874E3118A Q38747100-31FFC167-E86F-42C0-A4EF-5FA2AC1B3D63 Q38747419-C53F7A98-A93F-4A9C-ACC5-8B2091A72538 Q38750505-C0126CDA-98AB-483C-A708-53742D9F183A Q38771884-11E7E773-E018-4C8D-9FC3-8874091E50A2 Q42361890-A28E6E75-6D73-4861-B778-B94F8AEA2EB6 Q42369871-F5C3DB10-5690-45B2-816D-2378BCFEE9AA Q43482708-57F71AC1-5BC4-41DD-81A4-D2805430D8A2 Q43735862-38876286-D837-43F7-B312-3FF0B45D1072 Q47290604-F358FFF6-691D-4306-BDB1-B183DF5483E3 Q47983705-E35D92EA-3CBD-41F6-9BB5-545CDFF89B35 Q50042914-598AFB49-43E7-4407-97F0-1EA6B86E5C22 Q53507006-497898FF-4561-40E7-8E30-015F41417C5F Q54125905-76B78437-1F53-42CC-AB5B-5B0D07EE2AA9 Q54333269-2AA1492A-00C4-4804-BE59-3074599F4483 Q56523156-D2397420-2AE5-423B-B25C-F3A8C6B8ABCF Q58788563-3A3287E9-E282-43DC-96A0-DD5BDC444C34

P2860

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

http://www.wikidata.org/entity/Q34326110

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@ast

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@en

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@nl

type

label

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@ast

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@en

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@nl

prefLabel

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@ast

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@en

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@nl

P1433

Q34326110-D3B1C9DB-BF1D-4424-B25E-D96AC0EDE4C9

P1476

Q34326110-F0AA33EC-4199-4431-B2D3-251D6FAD81CB

P2093

Q34326110-19B644FE-DA0C-42FD-9D76-AB5B8B90A378

Q34326110-34B0B19A-2634-40F4-8D41-DA85CED78093

Q34326110-3682E968-7291-4686-9949-DC1978D91026

Q34326110-4364D850-2543-475E-8460-7E6409232F5A

Q34326110-5D58491B-235F-46C5-B204-306346B4D727

Q34326110-66B9E5A1-DDEE-41F8-A570-75856A8776B9

Q34326110-AB1D42B5-F35F-4EA4-9F03-BD9A92818471

Q34326110-CFC15E5D-E8E2-4A3F-95E9-28C081679089

Q34326110-D0060AEA-005C-4BB0-B3DD-820512DEDC19

P2860

Q34326110-05F926A5-5569-4EB4-86BC-D370A2E71CE6

Q34326110-14ED94D1-09FD-4360-92B9-42B29608EFF7

Q34326110-1CE3A38E-93D3-4226-AB07-39224301E5D9

Q34326110-399CE7EB-D773-401E-9572-9A4104FD5900

Q34326110-3A3C3224-74CC-4A00-BCEA-7FE56E852557

Q34326110-45EA29CF-D203-430E-8F64-3FB797F09047

Q34326110-4E96EF0D-3C14-4002-BE14-40353B6BFD31

Q34326110-4EC8D82E-B0D0-49DA-BCB3-81EE0FD4D501

Q34326110-6706C5C1-47F0-4510-9F37-F93B265520EB

Q34326110-6C3818C1-CA58-4369-B966-F1AFD52C464E

P304

Q34326110-EB038AD1-DA8A-4CA5-A819-88841BA7C5FB

P31

Q34326110-F9E6908E-80D4-4E13-8C2B-AA62D3407D3E

P356

Q34326110-63D3FC8A-0CC2-49B4-A5B0-31586D1A919D

P407

Q34326110-A949F448-65D5-4EE6-9DEB-3038120986DF

P433

Q34326110-841A09F9-3591-41FA-ACB9-94B68AC8A726

P478

Q34326110-85A403C9-3356-48C3-82FE-F9378556A99A

P577

Q34326110-2446B175-0559-480B-B81B-D284B3206182

P5875

Q34326110-7EC28291-40F4-438B-9ED3-E0807E21E040

P698

Q34326110-B758C3E4-6D4A-4DE1-9617-9F0C809A5B8E

P932

Q34326110-B35E0A1B-4045-44D5-9412-1FEF4CD23578

P356

JOURNAL.PONE.0039416

P1433

P1476

Human peripheral blood mononuc ...... lemtuzumab mediated cytolysis.

@en

P2093

Bruce L Roberts

http://www.w3.org/2001/XMLSchema#string

Johanne M Kaplan

http://www.w3.org/2001/XMLSchema#string

Jose Sancho

http://www.w3.org/2001/XMLSchema#string

Juanita Campos-Rivera

http://www.w3.org/2001/XMLSchema#string

Paula M Boutin

http://www.w3.org/2001/XMLSchema#string

Peter B Severy

http://www.w3.org/2001/XMLSchema#string

Sambasiva P Rao

http://www.w3.org/2001/XMLSchema#string

Srinivas Shankara

http://www.w3.org/2001/XMLSchema#string

Timothy Weeden

http://www.w3.org/2001/XMLSchema#string

P2860

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

Reshaping human antibodies for therapy

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Heterogeneity of human peripheral blood monocyte subsets.

Control of the complement system.

CD52 (CAMPATH1).

The CD52 antigen and development of the CAMPATH antibodies.

P304

e39416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0039416

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228116525

http://www.w3.org/2001/XMLSchema#string

P698

22761788

http://www.w3.org/2001/XMLSchema#string

P932

3382607

http://www.w3.org/2001/XMLSchema#string